MARKET

FDMT

FDMT

4D Molecular Therapeutics Inc.
NASDAQ
10.75
+0.20
+1.90%
After Hours: 10.75 0 0.00% 19:34 08/07 EDT
OPEN
10.66
PREV CLOSE
10.55
HIGH
10.84
LOW
10.45
VOLUME
346.90K
TURNOVER
--
52 WEEK HIGH
14.00
52 WEEK LOW
5.11
MARKET CAP
561.97M
P/E (TTM)
-3.9853
1D
5D
1M
3M
1Y
5Y
1D
4D Molecular Therapeutics' Gene Therapy Pipeline Faces Its First Real Commercial Scrutiny
Barchart · 1d ago
Weekly Report: what happened at FDMT last week (0727-0731)?
Weekly Report · 5d ago
4D Molecular Therapeutics Initiated at Buy by B. Riley Securities
Dow Jones · 07/31 16:02
4D Molecular Therapeutics Price Target Announced at $37.00/Share by B. Riley Securities
Dow Jones · 07/31 16:02
B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37
Benzinga · 07/31 15:52
Roblox downgraded, Quanta Services upgraded: Wall Street’s top analyst calls
TipRanks · 07/31 13:50
4D Molecular initiated with a Buy at B. Riley
TipRanks · 07/31 12:36
Weekly Report: what happened at FDMT last week (0720-0724)?
Weekly Report · 07/27 09:17
More
About FDMT
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company advancing durable and disease-targeted therapeutics. The Company's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The Company is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The Company's non-core programs include 4D-175, 4D-725, and 4D-310.

Webull offers 4D Molecular Therapeutics Inc stock information, including NASDAQ: FDMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FDMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FDMT stock methods without spending real money on the virtual paper trading platform.